Safety and effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen in patients with metastatic castration-resistant prostate cancer with and without visceral metastases who had received prior radium-223: a post hoc analysis of the RALU study

被引：0
|
作者：
Rahbar, Kambiz [1 ]
Essler, Markus [2 ]
Eiber, Matthias [3 ]
la Fougere, Christian [4 ]
Prasad, Vikas [5 ]
Pabst, Kim [6 ]
Fendler, Wolfgang [7 ]
Rassek, Philipp [8 ]
Hasa, Ergela [9 ]
Dittmann, Helmut [4 ]
Bundschuh, Ralph [10 ]
Kurtinecz, Milena [11 ]
Schmall, Anja [12 ]
Verholen, Frank [12 ]
Sartor, Oliver [13 ]
机构：
[1] Univ Hosp Munster, Dept Nucl Med, Munster, Germany
[2] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
[3] Tech Univ Munich, Munich, Germany
[4] Univ Hosp Tubingen, Dept Nucl Med & Clin Mol Imaging, Tubingen, Germany
[5] Univ Ulm, Dept Nucl Med, Ulm, Germany
[6] Univ Hosp Essen, Dept Nucl Med, West German Canc, Essen, Germany
[7] Univ Hosp Essen, Essen, Germany
[8] Univ Munster, Dept Nucl Med, Med Ctr, Munster, Germany
[9] Tech Univ Munich, Nucl Med, Klinikum Rechts Isar, Munich, Germany
[10] Univ Hosp Augsburg, Nucl Med, Fac Med, Augsburg, Germany
[11] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[12] Bayer Consumer Care, Basel, Switzerland
[13] Tulane Med Sch, Tulane Canc Ctr, New Orleans, LA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P607
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety and Effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen (177Lu-PSMA) Therapy Used in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Radium-223 (223Ra): The RALU Study
    Rahbar, K.
    Essler, M.
    Eiber, M.
    La Fougere, C.
    Prasad, V.
    Fendler, W. P.
    Rassek, P.
    Hasa, E.
    Dittmann, H.
    Bundschuh, R. A.
    Pabst, K. M.
    Kurtinecz, M.
    Schmall, A.
    Verholen, F.
    Sartor, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S54 - S55
  • [2] Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.
    Rahbar, Kambiz
    Essler, Markus
    Eiber, Matthias
    La Fougere, Christian
    Prasad, Vikas
    Fendler, Wolfgang P.
    Rassek, Philipp
    Hasa, Ergela
    Dittmann, Helmut
    Bundschuh, Ralph A.
    Pabst, Kim M.
    Kurtinecz, Milena
    Sandstrom, Per
    Verholen, Frank
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes
    Rahbar, K.
    Essler, M.
    Eiber, M.
    la Fougere, C.
    Prasad, V.
    Fendler, W. P.
    Rassek, P.
    Hasa, E.
    Dittmann, H.
    Bundschuh, R. A.
    Pabst, K. M.
    Kurtinecz, M.
    Schmall, A.
    Verholen, F.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1180 - S1180
  • [4] Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study
    Rahbar, Kambiz
    Essler, Markus
    Pabst, Kim M.
    Eiber, Matthias
    la Fouge, Christian
    Prasad, Vikas
    Rassek, Philipp
    Hasa, Ergela
    Dittmann, Helmut
    Bundschuh, Ralph A.
    Fendler, Wolfgang P.
    Kurtinecz, Milena
    Schmall, Anja
    Verholen, Frank
    Sartor, Oliver
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (04) : 574 - 578
  • [5] Time interval between radium-223 (223Ra) therapy and Lutetium-177-prostate-specific membrane antigen (177Lu-PSMA) treatment and outcomes in the RALU study.
    Rahbar, Kambiz
    Essler, Markus
    Eiber, Matthias
    la Fougere, Christian
    Prasad, Vikas
    Pabst, Kim M.
    Fendler, Wolfgang Peter
    Rassek, Philipp
    Hasa, Ergela
    Dittmann, Helmut
    Bundschuh, Ralph A.
    Kurtinecz, Milena
    Schmall, Anja
    Verholen, Frank
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
    Prelaj, Arsela
    Rebuzzi, Sara Elena
    Buzzacchino, Federica
    Pozzi, Chiara
    Ferrara, Carla
    Frantellizzi, Viviana
    Follacchio, Giulia Anna
    Civitelli, Liana
    De Vincentis, Giuseppe
    Tomao, Silverio
    Bianco, Vincenzo
    ONCOLOGY LETTERS, 2019, 17 (02) : 1467 - 1476
  • [7] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Hiroji Uemura
    Hirotsugu Uemura
    Nobuaki Matsubara
    Seigo Kinuya
    Makoto Hosono
    Yoko Yajima
    Toshihiko Doi
    International Journal of Clinical Oncology, 2017, 22 : 954 - 963
  • [8] Efficacy and Safety of Radium-223 Dichloride in the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastases
    Sanchez Lopez, Hector
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 1 - 2
  • [9] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Uemura, Hiroji
    Uemura, Hirotsugu
    Matsubara, Nobuaki
    Kinuya, Seigo
    Hosono, Makoto
    Yajima, Yoko
    Doi, Toshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 954 - 963
  • [10] EFFICACY AND SAFETY ANALYSIS OF RADIUM-223 IN PATIENTS WITH PROSTATE CANCER CASTRATION-RESISTANT AND BONE METASTASIS
    Alvis-Guzman, N.
    Huerfano, L. M.
    Alvis-Zakzuk, N. J.
    Romero Prada, M. E.
    Alvis-Guzman, N.
    Huerfano, L. M.
    VALUE IN HEALTH, 2018, 21 : S16 - S17
12345